Palatin Technologies (PTN) Operating Leases (2020 - 2026)
Palatin Technologies' (PTN) quarterly Operating Leases came in at $97457.0 in Q1 2026, up 44.92% on a YoY basis from $67248.0 in Q1 2025, and down 24.49% quarter-over-quarter from $129061.0 in Q4 2025.
Analysis
Palatin Technologies (PTN) Operating Leases (2020 - 2026) Analysis & Trends
Palatin Technologies (PTN) has reported Operating Leases for 7 consecutive years, with $97457.0 the latest figure, recorded in Q1 2026.
- For the quarter ending Q1 2026, Operating Leases rose 44.92% year-over-year to $97457.0; the trailing twelve-month figure through Mar 2026 stood at $97457.0 (up 44.92% YoY), and the FY2025 full-year result was $33969.0, down 79.26% from the prior year.
- Operating Leases slipped to $97457.0 in Q1 2026 per PTN's latest filing, from $129061.0 in the prior quarter.
- Across five years, Operating Leases topped out at $621660.0 in Q1 2022 and bottomed at $33969.0 in Q2 2025.
- Historically, Operating Leases has averaged $292885.5 across 5 years, with a median of $291355.0 in 2023.
- The sharpest annual moves came in 2025 and 2026: Operating Leases slumped 79.26% in 2025, then jumped 44.92% in 2026.
- Over 5 years, Operating Leases stood at $380161.0 in 2022, then slipped by 5.9% to $357744.0 in 2023, then sank by 72.03% to $100071.0 in 2024, then increased by 28.97% to $129061.0 in 2025, then decreased by 24.49% to $97457.0 in 2026.
- According to Business Quant data, Operating Leases over the past three periods registered $97457.0, $129061.0, and $33969.0 for Q1 2026, Q4 2025, and Q2 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Palatin Technologies | 46.98 Mn | 46.98 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 97,457.00 |
| Dec 31, 2025 | 129,061.00 |
| Jun 30, 2025 | 33,969.00 |
| Mar 31, 2025 | 67,248.00 |
| Dec 31, 2024 | 100,071.00 |
| Sep 30, 2024 | 132,447.00 |
| Jun 30, 2024 | 163,782.00 |
| Mar 31, 2024 | 262,220.00 |
| Dec 31, 2023 | 357,744.00 |
| Sep 30, 2023 | 481,046.00 |
| Jun 30, 2023 | 544,323.00 |
| Mar 31, 2023 | 320,490.00 |
| Dec 31, 2022 | 380,161.00 |
| Sep 30, 2022 | 465,091.00 |
| Jun 30, 2022 | 529,398.00 |
| Mar 31, 2022 | 621,660.00 |
| Dec 31, 2021 | 715,893.00 |
| Sep 30, 2021 | 808,840.00 |
| Jun 30, 2021 | 900,520.00 |
| Mar 31, 2021 | 986,175.00 |